FDA
-
-
-
-
-
-
-
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
-
-
-
-
-
-
-
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
-
-
-
-
-
-
-
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
-
-
-
-
-
-
-
CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
-
-
-
-
-
-
-
The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
-
-
-
-
-
-
-
uniQure (QURE) announces FDA approval of first gene therapy for adults with hemophilia B
-
-
-
-
-
-
-
CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors
-
322,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

